[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Generics in Australia

November 2019 | 38 pages | ID: GB306776CEFEN
MarketLine

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Generics in Australia

SUMMARY

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Australian generics market had total revenues of $1.2bn in 2018, representing a compound annual growth rate (CAGR) of 1.6% between 2014 and 2018.
  • Market consumption volume increased with a CAGR of 5.5% between 2014 and 2018, to reach 59.8% of total pharma volume.
  • The subsidized cost of prescription medication through the Australian Pharmaceutical Benefits Scheme (PBS) for eligible patients has helped drive growth in the market share by making these products more widely available.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Australia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts by both value and volume
REASONS TO BUY
  • What was the size of the Australia generics market by value in 2018?
  • What will be the size of the Australia generics market in 2023?
  • What factors are affecting the strength of competition in the Australia generics market?
  • How has the market performed over the last five years?
  • How large is Australia’s generics market in relation to its regional counterparts?
1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. Which players have been most successful in the recent past (1-3 years)?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Mylan N.V.
8.3. Aspen Pharmacare Holdings Ltd
8.4. Apotex, Inc.

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. About MarketLine

LIST OF TABLES

Table 1: Australia generics market value: $ million, 2014-18
Table 2: Australia generics market volume: % of total pharma, 2014-18
Table 3: Australia generics market geography segmentation: $ million, 2018
Table 4: Australia generics market value forecast: $ million, 2018-23
Table 5: Australia generics market volume forecast: % of total pharma, 2018-23
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Mylan N.V.: key facts
Table 10: Mylan N.V.: Annual Financial Ratios
Table 11: Mylan N.V.: Key Employees
Table 12: Aspen Pharmacare Holdings Ltd: key facts
Table 13: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 14: Aspen Pharmacare Holdings Ltd: Key Employees
Table 15: Apotex, Inc.: key facts
Table 16: Apotex, Inc.: Key Employees
Table 17: Australia size of population (million), 2014-18
Table 18: Australia gdp (constant 2005 prices, $ billion), 2014-18
Table 19: Australia gdp (current prices, $ billion), 2014-18
Table 20: Australia inflation, 2014-18
Table 21: Australia consumer price index (absolute), 2014-18
Table 22: Australia exchange rate, 2014-18

LIST OF FIGURES

Figure 1: Australia generics market value: $ million, 2014-18
Figure 2: Australia generics market volume: % of total pharma, 2014-18
Figure 3: Australia generics market geography segmentation: % share, by value, 2018
Figure 4: Australia generics market value forecast: $ million, 2018-23
Figure 5: Australia generics market volume forecast: % of total pharma, 2018-23
Figure 6: Forces driving competition in the generics market in Australia, 2018
Figure 7: Drivers of buyer power in the generics market in Australia, 2018
Figure 8: Drivers of supplier power in the generics market in Australia, 2018
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2018
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2018
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2018

COMPANIES MENTIONED

Teva Pharmaceutical Industries Limited
Mylan N.V.
Aspen Pharmacare Holdings Ltd
Apotex, Inc.


More Publications